As previously reported, Guggenheim initiated coverage of NeoGenomics (NEO) with a Neutral rating and no price target The firm believes NeoGenomics has done a “great job” gaining share and driving volumes while expanding margin in the challenging area of diagnostics. However, while there is still potential, the firm believes the reality of coupling this base with higher growth and higher average selling price outpatient tests in order to drive margins and cash flow higher has “become more difficult than NEO likely anticipated” and views the potential as “more than captured in the relative premium valuations.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics initiated with a Neutral at Guggenheim
- NeoGenomics price target lowered to $12 from $18 at Piper Sandler
- NeoGenomics, Sherwin-Williams, Grab, Paccar, First Solar: Trending by Analysts
- NeoGenomics: Hold Rating Amid Mixed Performance and Uncertain MRD Pathway
- NeoGenomics price target lowered to $10 from $17 at Morgan Stanley
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue